Clover Biopharmaceuticals Ltd announced that Clinical Infectious Diseases has published additional data from the SPECTRA Phase 2/3 trial that showed the SCB-2019 COVID-19 vaccine reduced the risk of transmission to household members compared to placebo participants.
Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax Technologies Corp’s (NASDAQ: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
The study demonstrated that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 compared to households where the infected household member was not vaccinated.
Related: China-Based COVID-19 Shot Neutralizes Omicron Subvariants.
Among the 134 household contacts of infected household members who had received SCB-2019, there was one COVID-19 case; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.
No cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019.
Clover is working towards completing regulatory submissions in China, Europe, and the World Health Organization for SCB-2019 by the end of 2022.
Price Action: DVAX shares closed at $11.88 on Tuesday.
See more from Benzinga
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron’s Dupixent
BioNTech, Ryvu Therapeutics Join Forces For Immuno-Modulatory Candidates
Six Billion Gallons of Drinking Water Reportedly Vanished Yesterday in the U.S. – And Every Day — This Co
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Related Quotes
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
Anavex Life Sciences said its experimental Alzheimer's treatment met the goals of a midstage study, leading AVXL stock to rocket early Friday.
Shares of Agenus (NASDAQ: AGEN) rose 12.5% on Friday. One big buyer was Values First Advisors, a financial advisory firm that bought 10,013 shares of the company and now owns 238,514 shares of Agenus. Agenus focuses on immuno-oncology therapies that boost the body's ability to fight cancer and infections by activating T-cell immune responses.
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
By Faith Ashmore, Benzinga
What does it mean when you get a faint line on a COVID test? There are a few possibilities. Doctors weigh in.
The virus is more likely to survive on certain foods, depending on the conditions in which they’re stored.
According to the World Health Organization, more than 38 million people worldwide were living with HIV at the end of last year. About 1.2 million people in the U.S. have HIV. In Montgomery County, more than 4,000 people are living with the disease. Montgomery County's Department of Health and Human Services Program Administrator Melvin Cauthen joins FOX 5 to discuss the county's goal of reducing new HIV infections by 90% before 2030.
Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months.
Although hard, it's not impossible, there are healthcare companies with solid earnings and dividend growth that can be had for less than a bill with Ben Franklin's picture on it. Gilead Sciences (NASDAQ: GILD) and Bristol Myers Squibb (NYSE: BMY) have posted triple-digit percentage gains over the past 10 years in revenue, earnings per share (EPS), and total return price. On top of that, shares of Gilead and Bristol can both be bought for less than $90 a share, at least for the time being.
Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.
The Laundress is voluntarily recalling about eight million laundry and cleaning products that may contain bacteria that can cause respiratory infections among immunocompromised people. The company said it was issuing the recall Thursday after first warning customers on Nov. 17 to stop using its products. The Laundress said last month it had identified “the potential presence of elevated levels of bacteria” in some of its products and was working with the U.S. Consumer Product Safety Commission.
It’s not your imagination. It seems like everyone is getting sick in Florida.
Cases of gonorrhea — the second most common STI — are skyrocketing in the U.S.
High intensity exercise may reduce the risk of metastatic cancer according to a new study. Here, experts explain what this means.
When everyone around them stops taking pandemic precautions, it gets harder for immunocompromised Americans to protect themselves against COVID.
But not all experts are convinced
After two years in the background, RSV and the flu have roared to the fore in pediatricians’ offices and children’s hospitals across the country. Pediatric hospitals have been strained for weeks by an early surge in common seasonal pathogens including respiratory syncytial virus, or RSV. Hospitalizations for RSV among kids under 5 are outpacing those for Covid-19, CDC data show.
Al Roker returns to hospital due to blood clot 'complications'
Is lecanemab worth the risk?
